Conditioning for Patients With Aplastic Anemia Undergoing Allogeneic HSCT
Researchers assessed the safety and efficacy of a pretransplant conditioning regimen in patients with aplastic anemia undergoing allogeneic transplantation.
Aplastic Anemia
Adding Eltrombopag to Immunosuppression Did Not Change Outcomes in Pediatric Severe Aplastic Anemia
Researchers found that the addition of eltrombopag to standard immunosuppression therapy did not provide therapeutic benefit to pediatric patients with SAA.
Outcomes With Granulocyte Colony-Stimulating Factor in Therapy for Severe Aplastic Anemia
Researchers found similar incidences of late events in patients who were treated with and without granulocyte colony-stimulating factor.
Immunosuppressive Therapy in Pediatric Patients With Severe Aplastic Anemia
More than two-thirds of patients receiving horse antithymocyte globulin plus cyclosporine achieved a very good partial response or better.
Second-Line Treatment Options for Aplastic Anemia
Second-line treatment strategies for severe aplastic anemia include stem cell transplant, immunosuppressive therapy, and thrombopoietin mimetics.
Safety of Allogeneic HSCT for Patients With Hepatitis-Associated Aplastic Anemia
Patients demonstrated a 5-year overall survival rate of 86%, with all but 2 patients achieving neutrophil engraftment.
Determining Response and Outcomes With Eltrombopag Treatment for Refractory Severe Aplastic Anemia
Of 20 patients who showed response to eltrombopag at 24 weeks, 25% had not shown response at 12 weeks.
Promacta Approved as First-Line Treatment for Severe Aplastic Anemia
The approval was based on data from a single-arm, open-label sequential cohort study in which patients received Promacta in combination with horse antithymocyte globulin (h-ATG) and cyclosporine.
Cost of First-Line Eltrombopag to Treat Severe Aplastic Anemia
Eltrombopag plus IST was compared with IST alone in a simulated population of 1 million patients with severe aplastic anemia.
Aplastic Anemia Outcomes Examined for Anti-Thymoglobulin-Based IST
The researchers found that OS was superior in IST responders. Shorter relapse-free survival (RFS) was seen with partial response to IST compared with complete response.
